Sentence examples for comparator studies of from inspiring English sources
However, a number of issues pertain to comparator studies of possible estimators; in particular data structure and the full assessment, or otherwise, of model specification.
The dearth of head-to-head comparator studies of glucose-lowering medications, either alone or in combinations, and of trials that have lasted >6 12 months to examine the durable effects of interventions on glycemic control (10, 11, 20, 21) has hampered the development of all these algorithms.
Because treat-to-target trials essentially equalize glycaemic efficacy of the agents under study, the evaluation of differences in other measures of utility may differ from those used in traditional efficacy trials, such as placebo-controlled or active comparator studies of oral antidiabetic agents (OADs).
The same database also reported a meta-analysis of the suicide-related events reported from comparator studies of atomoxetine and methylphenidate and reported no difference in rates between these agents (Maentzel-Haentzel incidence difference -0.12 (95% confidence interval -0.62 to 0.38; p = 0.649).
52 In contrast, the randomized comparative PATRONUS (comPArator sTudy of CERA and darbepOetin alfa in patieNts Undergoing dialySis) trial 53 conducted with 490 HD patients demonstrated a dose increase of 6.8% after switching from once-weekly DA to once-monthly CERA.
The RECORD study was an open-label, 5.5-year randomized active comparator study of rosiglitazone against metformin or sulfonylurea (50% of each) (12).
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia ClinicalTrials.gov identifier: NCT01086748.
These trials were placebo-controlled or active-comparator studies of saxagliptin (2.5, 5, or 10 mg/d in most studies; 20, 40, or 100 mg/d in 1 phase 2b study) as monotherapy or add-on therapy to metformin, a sulfonylurea, a thiazolidinedione, or insulin ± metformin for up to 206 weeks (including long-term extension studies) in patients with T2DM (Table 1).
Of the FFP comparator studies analysed, only 38%2020 of 52) compared FFP with no FFP or with a non blood product (for example, colloid or crystalloid).
Of the comparator studies reporting the effect of FFP on blood loss, one reported lower blood loss as a result of FFP [ 34].
The lack of direct comparator studies led to an indirect comparison of the efficacy and tolerability of duloxetine with that of pregabalin and gabapentin in participants with painful DSPN, using placebo as a common comparator (78).
